The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100
Open accessAbstract
Bicyclams, in which the cyclam (1,4,8,11-tetraazacyclotetradecane) moieties are tethered via an aliphatic bridge (i.e., propylene, as in JM2763) are potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) (E. De Clercq, N. Yamamoto, R. Pauwels, M. Baba, D. Schols, H. Nakashima, J. Balzarini, Z. Debyser, B. A. Murrer, D. Schwartz, D. Thornton, G. Bridger, S. Fricker, G. Henson, M. Abrams, and D. Picker, Proc. Natl. Acad. Sci. USA 89:5286-5290, 1992). We have now found that the bicyclam JM3100, in which the cyclam moieties are tethered by an aromatic bridge [i.e., phenylenebis(methylene)], inhibits the replication of various HIV-1 and HIV-2 strains in various cell lines at a 50% effective concentration (EC50) of 1 to 10 ng/ml, which is about 100-fold lower than the concentration required for JM2763 to inhibit HIV replication and at least 100,000-fold lower than the cytotoxic concentration (> 500 micrograms/ml). In primary T4 lymphocytes or primary monocytes, JM3100 proved inhibitory to HIV-1(IIIB) and several clinical HIV-1 isolates at an EC50 of less than 1 ng/ml. On the basis of time-of-addition experiments, JM3100 appeared to interact with a viral uncoating event, and this was further corroborated by an uncoating assay in which RNase sensitivity of [5-3H]uridine-labeled virions was monitored. In addition, but possibly mechanistically related, JM3100 blocks formation of infectious particles. JM3100 was also found to interfere directly with virus-induced syncytium formation, albeit at a higher concentration (1 to 2 microgram/ml) than that required for inhibition of viral replication. Following subcutaneous injection of 10 mg of JM3100 per kg of body weight to rabbits, anti-HIV activity was detected in serum corresponding to serum drug levels exceeding for at least 6 h by >100-fold the EC(50) required to inhibit HIV replication in vitro. When combined with either 3'-azido-2',3' -dideoxythymidine or 2',3' -dideoxyinosine, JM3100 achieved a additive inhibition of HIV replication, and when repeatedly subcultivated in the presence of JM3100, the virus remained sensitive to the compound for at least 30 passages (120 days) in cell culture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., & De Clercq, E. (1988) · Journal of Virological Methods · doi:10.1016/0166-0934(88)90134-6 · Cited by 1,642
Self-citationRational Design of Peptide-Based HIV Proteinase Inhibitors
Roberts, N. A., Martin, J. A., Kinchington, D., Broadhurst, A. V., Craig, J. C., Duncan, I. B., Galpin, S. A., Handa, B. K., Kay, J., Kröhn, A., et al. (1990) · Science · doi:10.1126/science.2183354 · Cited by 929
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives
Pauwels, R., Andries, K., Desmyter, J., Schols, D., Kukla, M. J., Breslin, H. J., Raeymaeckers, A., Gelder, J. V., Woestenborghs, R., Heykants, J., et al. (1990) · Nature · doi:10.1038/343470a0 · Cited by 756
Self-citationA three-dimensional model to analyze drug-drug interactions
Prichard, M. N., & Shipman, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90001-n · Cited by 544
Baba, M., Pauwels, R., Balzarini, J., Arnout, J., Desmyter, J., & De Clercq, E. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.6132 · Cited by 465
Self-citationMitsuya, H., Looney, D. J., Kuno, S., Ueno, R., Wong-Staal, F., & Broder, S. (1988) · Science · doi:10.1126/science.2452480 · Cited by 463
Perno, C. F., Yarchoan, R., Cooney, D. A., Hartman, N. R., Webb, D. S., Hao, Z., Mitsuya, H., Johns, D. G., & Broder, S. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.3.933 · Cited by 285
Balzarini, J., Neyts, J., Schols, D., Hosoya, M., Van Damme, E., Peumans, W., & De Clercq, E. (1992) · Antiviral Research · doi:10.1016/0166-3542(92)90038-7 · Cited by 242
Self-citationDe Clercq, E., Yamamoto, N., Pauwels, R., Baba, M., Schols, D., Nakashima, H., Balzarini, J., Debyser, Z., Murrer, B. A., & Schwartz, D. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5286 · Cited by 242
Self-citationBalzarini, J., Schols, D., Neyts, J., Van Damme, E., Peumans, W., & De Clercq, E. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.3.410 · Cited by 231
Self-citation
Cited by
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Marsault, E., & Peterson, M. L. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1012374 · Cited by 843
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor
Donzella, G. A., Schols, D., Lin, S. W., Esté, J. A., Nagashima, K. A., Maddon, P. J., Allaway, G. P., Sakmar, T. P., Henson, G., DeClercq, E., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-072 · Cited by 760
Self-citationStructure, Function, and Inhibition of Chemokines
Fernandez, E. J., & Lolis, E. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.091901.115838 · Cited by 609
Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4
Schols, D., Struyf, S., Damme, J. V., Esté, J. A., Henson, G., & Clercq, E. D. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1383 · Cited by 554
Hendrix, C. W., Flexner, C., MacFarland, R. T., Giandomenico, C., Fuchs, E. J., Redpath, E., Bridger, G., & Henson, G. W. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1667-1673.2000 · Cited by 504
CXCR7 Functions as a Scavenger for CXCL12 and CXCL11
Naumann, U., Cameroni, E., Pruenster, M., Mahabaleshwar, H., Raz, E., Zerwes, H.-G., Rot, A., & Thelen, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009175 · Cited by 470
CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers
Burger, J. A., & Peled, A. (2009) · Leukemia · doi:10.1038/leu.2008.299 · Cited by 462
De Clercq, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1134 · Cited by 460
Self-citationChemokine receptor inhibition by AMD3100 is strictly confined to CXCR4
Hatse, S., Princen, K., Bridger, G., De Clercq, E., & Schols, D. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03143-5 · Cited by 448
Self-citationHendrix, C. W., Collier, A. C., Lederman, M. M., Schols, D., Pollard, R. B., Brown, S., Jackson, J. B., Coombs, R. W., Glesby, M. J., Flexner, C. W., et al. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000137371.80695.ef · Cited by 366
Guo, Z., & Sadler, P. J. (1999) · Advances in Inorganic Chemistry · doi:10.1016/s0898-8838(08)60271-8 · Cited by 354
Cyclam complexes and their applications in medicine
Liang, X., & Sadler, P. J. (2004) · Chemical Society Reviews · doi:10.1039/b313659k · Cited by 322
The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil)
De Clercq, E. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.12.014 · Cited by 277
Self-citationGerlach, L. O., Skerlj, R. T., Bridger, G. J., & Schwartz, T. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010429200 · Cited by 260
Rodríguez-Rodríguez, C., Telpoukhovskaia, M., & Orvig, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.008 · Cited by 151
Metadata
- Authors
- De Clercq, E., Yamamoto, N., Pauwels, R., Balzarini, J., Witvrouw, M., De Vreese, K., Debyser, Z., Rosenwirth, B., Peichl, P., & Datema, R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1994-04
- Volume
- 38
- Issue
- 4
- Pages
- 668-674
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2003239995
- Cited by
- 296
- References
- 15
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.